MOH
- Marketing authorisation holder: AYRMID PHARMA
- Status: likely_approved
Aphexda (MOTIXAFORTIDE) regulatory status in Israel.
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. MOH has authorised it.
AYRMID PHARMA holds the Israeli marketing authorisation.